Table S9 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer

Table S9 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer

<p>Table S9: Results of ATAC-seq of primary and TONSL-immortalized cells.</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Aditi S. Khatpe (15293176) (author)
Altres autors:	Rebecca Dirks (15293179) (author), Poornima Bhat-Nakshatri (15293182) (author), Henry Mang (15293185) (author), Katie Batic (15293188) (author), Sarah Swiezy (15293191) (author), Jacob Olson (15293194) (author), Xi Rao (15293197) (author), Yue Wang (15293200) (author), Hiromi Tanaka (15293203) (author), Sheng Liu (15293206) (author), Jun Wan (15090186) (author), Duojiao Chen (15293209) (author), Yunlong Liu (15293212) (author), Fang Fang (14946450) (author), Sandra Althouse (15293215) (author), Emily Hulsey (15293218) (author), Maggie M. Granatir (15293221) (author), Rebekah Addison (15293224) (author), Constance J. Temm (15293227) (author), George Sandusky (15293230) (author), Audrey Lee-Gosselin (15293233) (author), Kenneth Nephew (15293236) (author), Kathy D. Miller (15045080) (author), Harikrishna Nakshatri (14946969) (author)
Publicat:	2025
Matèries:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Carcinogenesis DNA Damage and Repair Small Molecule Agents
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Table S1 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S10 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S11 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S12 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S13 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S14 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S15 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S2 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S3 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S4 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Supplementary Figure S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Table S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S14 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S15 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S16 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S17 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S18 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S19 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S2 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S20 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S21 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S6 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Figure S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Table S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Table S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Table S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Table S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Table S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Table S2 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Table S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Supplementary Table S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
per: Chuandong Geng (17315310)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_kthc0fp14a5a3ia591kg74ntnh